MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
cbdMD Total Non Current Liabilities 2011-2026 | YCBD
Annual Total Non Current Liabilities cbdMD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.49 M | 4.08 M | 14.8 M | 24 M | 53.2 M | 28.5 K | 397 K | 12 K | 4 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.2 M | 4 K | 11 M |
Quarterly Total Non Current Liabilities cbdMD
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 201 K | 400 K | 592 K | - | 2.96 M | 4.53 M | 2.09 M | 2.49 M | 2.85 M | 3.22 M | 3.58 M | 4.08 M | 4.81 M | 7.18 M | 8.17 M | 14.8 M | 19.5 M | 14.8 M | 31.6 M | 24 M | 24 M | 24 M | 40.8 M | 53.2 M | 53.2 M | 53.2 M | 76.5 M | 28.5 K | 28.5 K | 76.5 M | 375 K | 397 K | 397 K | 397 K | - | 12 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 76.5 M | 12 K | 16.3 M |
Total Non Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
134 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
6.61 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
23.9 M | $ 3.21 | 2.89 % | $ 45.1 M | USA |
 |
Cronos Group
CRON
|
10.7 M | $ 2.57 | -0.19 % | $ 1.34 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
316 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Sundial Growers
SNDL
|
1.03 M | $ 1.4 | 1.82 % | $ 3.37 M | Canada |
 |
Bausch Health Companies
BHC
|
26.5 B | $ 5.73 | 0.17 % | $ 2.09 B | Canada |
 |
Tilray
TLRY
|
570 M | $ 6.81 | 1.34 % | $ 4.21 B | Canada |
 |
Harrow Health
HROW
|
19.8 M | $ 37.8 | 1.89 % | $ 1.39 B | USA |
 |
Aurora Cannabis
ACB
|
681 M | $ 3.52 | 1.15 % | $ 86.3 M | Canada |
 |
Veru
VERU
|
6.71 M | $ 2.37 | -0.42 % | $ 320 M | USA |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
107 M | $ 1.44 | 1.06 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | USA |
 |
Viatris
VTRS
|
13.8 B | $ 13.95 | 0.87 % | $ 16.7 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
102 M | $ 4.35 | 0.35 % | $ 280 M | USA |
 |
Emergent BioSolutions
EBS
|
1.02 B | $ 8.63 | 4.73 % | $ 442 M | USA |
 |
Organogenesis Holdings
ORGO
|
105 M | $ 2.46 | 3.15 % | $ 324 M | USA |
 |
Pacira BioSciences
PCRX
|
368 M | $ 23.78 | -1.16 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
7.94 M | - | - | $ 5.07 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 7.28 | -1.36 % | $ 287 M | USA |
 |
Assertio Holdings
ASRT
|
115 M | $ 18.02 | 0.03 % | $ 115 M | USA |
 |
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
53.4 M | $ 1.02 | 0.99 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
34 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
19.1 M | $ 8.31 | -0.95 % | $ 727 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 2.29 | -2.71 % | $ 2.84 M | USA |
 |
Zomedica Corp.
ZOM
|
275 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
110 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
11.6 M | $ 0.91 | -2.92 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
13.2 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
1.71 M | $ 0.63 | -3.05 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
246 M | $ 2.09 | 1.96 % | $ 24.2 M | USA |